Tag Archives: BIO CEO & Investor Conference

Industry Outlook in Anticipation of the 2012 BIO International Convention

HC5O7460

This month, BIO wrapped the 14th Annual CEO & Investor Conference in New York City at the Waldorf=Astoria. Hosted by BIO, the event drew more than 1,200 industry leaders, featured 140 company presentations and a record breaking 1,300+ one-on-one meetings between 225 companies. Taking the momentum from this meeting, we now look ahead to the 2012 BIO International Convention to be held June 18 – 21, 2012 at the Boston Convention & Exhibition Center in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at the Waldorf=Astoria Hotel in New York City. Meetings scheduled between institutional investors and biotech executives hit a record high and the opening plenary was a standing room only event. Kicking off the plenary were opening remarks from BIO’s Executive Vice President of Emerging Companies and Business Development, Alan Eisenberg. A copy of the slides can be found here: Opening Plenary Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second place. Not so bad considering 2011 was the year of defense in the stock market. Like a page out of a textbook on defensive market plays, utilities edged out ahead with a +15% gain, followed by consumer staples with 11%. The NBI squeezed in between at 12%, just above the overall healthcare sector. Overall, the S&P500 was flat for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,